Omnicare — Conference Presentation (February 2013)
37 slides from Omnicare's conference presentation, Feb 25, 2013
Slide 1: Omnicare
Omnicare
Slide 2: Omnicare
Omnicare
Slide 3: Forward-Looking Statements
Forward-Looking Statements Certain of the statements made today and listed within ji ion slides are f rd-looki ‘statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-| looking statements include, but: are not limited to, all statements regarding the int
Slide 4: Long-Term Care Group
Long-Term Care Group came ; in Business Overview Customers Market Position Annual Prescriptions Specialty Care Group Wl
Slide 5: Omnicare's Primary Businesses
| Omnicare’s Primary Businesses By the Numbers 2012 Revenue 2012 Adjusted Operating Income 2) $10.3M $4,848.3M mLong Term Care mSpecialty Care = Other Long Term Care mSpecialty Care = Other While LTC represents majority of operating income, SCG growth has recently outpaced LTC page Adjusted op find
Slide 6: Increased Shareholder Value
LTC Organic Growth SCG Momentum Efficient Capital Allocation Increased Shareholder Value
Slide 7: Market Trends
Market Trends
Slide 8: Demographic Trends
| 2 Demographic Trends Aging Population Shaping US Healthcare Systems") 450,000,000 425,000,000 400,000,000 Under 65 375,000,000 350,000,000 U.S. Population 325,000,000 300,000,000 275,000,000 250,000,000 Seniors’ utilization of pharmaceuticals is more than three times higher than the general popula
Slide 9: Specialty Pharmaceutical Market Trends
Specialty Pharmaceutical Market Trends Continued Growth for the Foreseeable Future’) US Drug Spend Market Share — US Drug Spend Market Share — 2011 2016 => mTraditional Drugs = Specialty Drugs = Traditional Drugs = Specialty Drugs Specialty drug market continues to grow rapidly through increased uti
Slide 10: Specialty Pharmaceutical Market Trends
| Specialty Pharmaceutical Market Trends Pharmaceutical Pipeline Abundant with Specialty Products‘) Marketed & Approved Products Pipeline Products Specialty Drugs 8% ‘Specialty Drugs 42% Traditional Drugs 92% Traditional Drugs 58% 0% 25% + 50% += 75% © 100% 0% — 20% © 40% © 60% + 80% Market Share Sh
Slide 11: Long-Term Care Group
Long-Term Care Group
Slide 12: Long-Term Care Group
Long-Term Care Group Institutional Pharmacy Value Proposition o —_— adh Pharmacy Technology Operations , ‘ Services zg SNF chart reviews E Regular point of contact Packaging Payer source verification a for customer 24/7 medication delivery to meet admission schedule S Industry standard Refill s Geri
Slide 13: Omnicare Clinical Services
Omnicare Clinical Services Clinical Tools Designed to Improve Quality of Care | ees J " Lae] - — Long-Term Care Group 4. Varies by customer, based on Omnicare intl data 32 omnicare
Slide 14: Omnicare Pharmacy Operations
Omnicare Pharmacy Operations Infrastructure Ensures National Reach * * 2 ih n nt ® 2 * i al * ‘ef ; a ot ® ® * *. * * Omnicare’s network includes 32 regional hubs and over 120 spoke pharmacy locations 32 omnicare
Slide 15: Omnicare Technology Services
Omnicare Technology Services Technology Offering Fully Integrated Through Omniview™ Omnicare’s secure web-based worksite for customer facilities, prescribers and patients Classic Omniview OmniviewDr
Slide 16: Refining Long-Term Care Focus
Refining Long-Term Care Focus Three-Phase Operational Plan for Sustainable Growth Phase 1: Phase 2: Phase 3: First 100 Days Day 101 thru 2Q13 3Q13 and Beyond + Operating discipline + Acton Phase 1 takeaways Assess the benefits realized — Accountability = Improve structure: realign five during Phase
Slide 17: Establishing Consistent Organic Growth in LTC
‘a Establishing Consistent Organic Growth in LTC Leveraging Omnicare’s Assets * Controllable organic growth dependent on... Retention SEICS + Operational excellence Understand market initiatives to drive service opportunities improvements Align value proposition to Expanded technology market needs o
Slide 18: Continued Emphasis on Controlling Bed Losses
Privileged & Confidential Continued Emphasis on Controlling Bed Losses Heightened Focus on the Underperformers * Hub performance and retention inconsistent - Six regional service areas significantly underperforming * Opportunity to increase organic growth potential by standardizing operations across
Slide 19: Sales Initiatives Key to Improving Results
Sales Initiatives Key to Improving Results Sales Transformation Focused on Enhancing Selling Effectiveness Resources not aligned with opportunities — Best sales resources not focused on highest-potential areas Value proposition not communicated consistently Structure not maximizing resources — Rebal
Slide 20: Refining Long-Term Care Focus on Operations
Refining Long-Term Care Focus on Operations Expectations for Three-Phase Plan + Upon completion of our operational plan, we expect: — Improved retention — Increased sales Retention Rate Expectations Organic Sales Expectations 4 2012 adie 92.3%, Retention Rate New Bed Additions Improved sales and con
Slide 21: Refining Long-Term Care Focus
(7 Refining Long-Term Care Focus Identifying Fastest Growing Segment of the Senior Housing Market Senior Housing Occupancy Trends) .. Se a= oe —— NONE ee 8 os S og RS RSS A FFE FEF PEAK KM gw Mm gy gS 8 SHSM PSP eg PPP IP IS SF Ss f —Skilled Nursing ©——Assisted Living ——Independent Living While seni
Slide 22: Additional Focus on Growing Assisted Living Market
Refining Long-Term Care Focus Additional Focus on Growing Assisted Living Market * Assisted Living Communities — Customized programs targeted at assisted living market — Three-pronged growth opportunity Assisted Living Opportunity MSIE Sepals) Grow with Industn Penetration Rate Customer Base y 2% om
Slide 23: Omnicare Specialty Care Group
RNY Wy, ys Ommicare Specialty Care Group
Slide 24: Specialty Care Group
Specialty Care Group Omnicare’s Five Operating Platforms Brand Supply Patient Specialty End of Life Support Chain Support Pharmacy are Services Solutions Services @revency Third Party A Buy/Sell Per Diem Revenue Fee for Service Model Model Model Product Manufacturer owns the product SCG owns the pro
Slide 25: Manufacturer focused
D) Manufacturer focused Efficient & timely capture of data, Enhanced speed to therapy effective brand decisions Flexible solutions adaptable Cost optimized to specific brand needs Seamless, “One” patient experience
Slide 26: Specialty Care Group
Specialty Care Group Continuing SGC Growth Momentum Revenue mmmRevenues —»~Adjusted Operating Profit” Operating Profit a eons {in $milions) $400.0 | $40.0 $350.0 — $35.0 $300.0 $30.0 $250.0 + $25.0 $200.0 $20.0 “EVP hired +s0e orm + Evaluation of ‘existing SP operations ‘investors’ page.
Slide 27: Specialty Care Group
Specialty Care Group Maximizing Internal and External Opportunities Omnicare specialty care growth has been robust... and opportunities exist to further accelerate growth through: Continued improvements to the organizational structure — Investments made to support solutions sales process — Platform-
Slide 28: Financial Overview
Financial Overview
Slide 29: Operating Performance
Operating Performance Eight-Quarter Trend") (in millions, except percentage data) 34.0 85% 84% ia 83% + 30.0 82% + 280 bs 260 240 78% 77% 22.0 nee 200 75% 1Q11 2011 3QIt 4Qit 1012 2Q12 sa1z 4a12 1Q11 2011 3QIt 4Qr1 1012 2Q12 sQ12 4Q12 '=Presription Dispensed ‘= Generic Dispense Rate $1,700 $1,600 $1
Slide 30: Focus on Cash Flow
Privileged & Confidential Focus on Cash Flow Cash Flow Drives Substantial Value Highly compelling financial attribute is cash flow generation capability — High quality of earnings — Creates flexibility for capital allocation initiatives Quarterly Adjusted EBITDA” vs. CFFO (in $ millions) 1011 2a11 3
Slide 31: Capital Allocation Program
Capital Allocation Program Acquisitions + Disciplined approach to acquisitions — Minimum 15% after-tax returns — Strong operations without compliance issues - LTC — Strong growth trajectory to justify multiples - SCG + More disciplined approach has reduced the number and amount of acquisitions Histo
Slide 32: Capital Allocation Program
Capital Allocation Program Dividend Program Focused on Maintaining Reasonable Yield * Dividend program — Since 2Q10 the dividend has been increased four times, representing a greater than 500% increase — Current dividend rate yields 1.4%‘) and will continue to be reviewed Commitment to Dividend $45,
Slide 33: Capital Allocation Program
Capital Allocation Program Share Repurchases Focused on Increasing Returns, Reducing Shares « Share repurchases — From 2Q10-4Q12, Omnicare has repurchased 19.2 million shares at an average price of $30.17 $400 120.0 $350 $250 tsa (in Smilions) g 8 Capital Returned by Shares Repurchases so 110.0 2009
Slide 34: Capital Allocation Program
Capital Allocation Program Debt Repayment Major Debt Maturity Schedule (in $ millions) As of 9/30/10 As of 12/31/12 2013-2014 20152016 =S 2017-2018 = 2019» 2020 2025 = 2033 2042 Capital restructuring initiatives have created more flexibility to raise capital for the right acquisition or gradually re
Slide 35: Credit Profile
Privileged & Confidential Credit Profile” Three-Year Trend + Debt/Total Capital 35.6% 34.5% 37.0% » Net Debt/Total Capital 29.7% 27.2% 31.4% | » Leverage Ratio (Debt to EBITDA) Non- GAAP: — Total Debt 4.28x 3.89x 3.66x | — Net Debt 3.45x 2.94x 2.99x — All Net Debt 2.78Xx 2.39Xx 2.45x * Cash Position
Slide 36: Full-Year 2013 Guidance
Full-Year 2013 Guidance | 12 Results % Change + Revenue $6.2B $6.1B to $6.2B -1.6% to 0.0% » Adjusted cash earnings a eS per diluted share) $3.36 $3.47 to $3.57 3.3% to 6.3% © Geciniionsiiom $544M $450M to $500M — -17.3% to -8.1% operations’) Midpoint of 2013 guidance reflects a 10.2% two-year CAGR
Slide 37: Omnicare
Omnicare